BILLERICA, Mass.—EMD Millipore, the life-science division of Merck KGaA, and Proteomics International recently announced a collaboration for the validation of biomarkers for diabetic nephropathy. Proteomics International’s 13 newly identified putative protein biomarkers, which include proteins involved in inflammation, metabolism and oxidative stress, will be assessed using EMD Millipore’s multiplex immunoassays. Several of the biomarkers could enhance the current screening method—a microalbumin test consisting of a single biomarker in urine—by identifying a signature of biomarkers in the blood that could better signify disease prediction and progression.  

 

“We are very excited to be working with EMD Millipore to progress our initial discovery of these biomarkers that could improve diagnosis and health outcomes on such a large scale,” said Dr. Richard Lipscombe, managing director of Proteomics International.